Drug Trial Radar · NCT05838092
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
Last checked: Nov 20, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
9
Actual
Start
Oct 18, 2023
Primary completion
Aug 29, 2025
Study completion Jul 2026
Sponsor
- Lead sponsor
- RHEACELL GmbH & Co. KGIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo. An additional baseline-controlled open-label arm will be included to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with JEB and to RDEB subjects \< 1 year.
Conditions
- Epidermolysis Bullosa
Interventions
allo-APZ2-OTSDrug
Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects with complete target wound closureTime frame: 6 Months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Colorado
Aurora, Colorado
Masonic Cancer Center and Medical Center Minneapolis
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.